Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility Shared Resource ABSTRACT The Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility (MMSBD) provides Cancer Center (CC) members with mass spectrometry (MS)-based multi-omics technology to support research on cancer pathogenesis, cancer biomarkers, novel anti-cancer agents, and diagnostic studies. The multi-omics approaches provided encompass high-quality MS services for proteomics, peptidomics, glycomics, lipidomics, metabolomics, and small molecule analyses. Quantitative phosphoproteomics and deep proteomics are new services provided during the current funding period. The Core offers scientific consultation from project conception and execution to preparation of manuscripts and grant applications. Primary Core services are: 1) liquid chromatographic/mass spectrometry (LC/MS); 2) untargeted/targeted proteomics, including label-free quantitative proteomics as well as stable isotope labeling with isobaric tandem mass tags or stable isotope labeling of amino acids in culture; 3) identification and quantification of post- translational modifications; 4) de novo peptide/protein sequence analysis; 5) peptide sequence validation under GMP conditions (the Core is FDA-registered); 6) lipidomics and metabolomics; 7) biomarker discovery from clinical samples; 8) assay development and quantification of small molecules, peptides, drugs, and validation of potential biomarkers; 9) tissue biomarker profiling by MALDI-MS; and 10) tissue imaging mass spectrometry. The MMSBD is well equipped with cutting-edge major instrumentation including an Orbitrap Fusion Tribrid mass spectrometer (Thermo); a 6490 Triple Quadrupole mass spectrometer (Agilent); several LC Q-TOF mass spectrometers (Waters and Agilent), and two MALDI-MS instruments. A second high-end Orbitrap mass spectrometer (a Fusion Lumos; Thermo) is being purchased to meet increased demands for LC/MS instrument time. Data analyses are performed on Core-maintained workstations and multi-node computer clusters that operate both commercial and open source software. Software is constantly updated and MS and metadata are automatically backed up and stored on several redundant storage units located on and off the main campus. The core is co-directed by Drs. Markus Kalkum and Robert Hickey, who are both faculty within Beckman Research Institute. Key decisions affecting the Core are reviewed by an Advisory Committee, composed of CC members who use the Core?s services. Since the last competitive renewal, the MMSBD contributed to 26 publications by CC members and served 73 investigators, 52 of whom were CC members representing all five Programs. Of the 52 CC members, 45 (87%) had peer-reviewed funding. Accordingly, the MMSBD provides accessible, cost-effective, and high-quality multi-omics mass spectrometry and biomarker discovery services to support the research of the City of Hope Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059204
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765
Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923
Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R
Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Chaurasiya, Shyambabu; Chen, Nanhai G; Fong, Yuman (2018) Oncolytic viruses and immunity. Curr Opin Immunol 51:83-90

Showing the most recent 10 out of 1396 publications